JP2006525368A5 - - Google Patents

Download PDF

Info

Publication number
JP2006525368A5
JP2006525368A5 JP2006514250A JP2006514250A JP2006525368A5 JP 2006525368 A5 JP2006525368 A5 JP 2006525368A5 JP 2006514250 A JP2006514250 A JP 2006514250A JP 2006514250 A JP2006514250 A JP 2006514250A JP 2006525368 A5 JP2006525368 A5 JP 2006525368A5
Authority
JP
Japan
Prior art keywords
ligand
lipid
alkyl
independently
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006514250A
Other languages
English (en)
Other versions
JP2006525368A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/013727 external-priority patent/WO2004098524A2/en
Publication of JP2006525368A publication Critical patent/JP2006525368A/ja
Publication of JP2006525368A5 publication Critical patent/JP2006525368A5/ja
Pending legal-status Critical Current

Links

Claims (1)

  1. 癌の治療方法であって、かかる治療を必要とする被験体に、癌治療に有効な量の式(I)で表される脂質白金錯体または式(I)で表される脂質白金錯体の製薬上許容可能な塩を投与することを含む、前記方法。
    式(I)：
    （式中、
    R1およびR2は、独立して-N(R6)2、-NH3 +であるか；あるいは、R1およびR2はそれぞれ-NH2であって、かつC2-C6アルキレンまたはC3-C7シクロアルキレン基を介して結合して、1個または複数のR7で置換されていてもよい二座ジアミンリガンドを形成しており；
    R3は脂質リガンドであり、但し、R3はホスファチジン酸ではなく；
    R4は脂質リガンド、無機リガンド、-CN、または-OC(O)R5であり、但し、R4はホスファチジン酸ではなく；
    R5は、C1-C24アルキルであり；
    各R6は、独立して、-H、-C1-C6アルキル、-C3-C7シクロアルキル、または-アリールであり；
    各R7は、独立して、-C1-C6アルキル、-C3-C7シクロアルキル、または-アリールである。）
JP2006514250A 2003-05-02 2004-05-03 脂質白金錯体およびその使用方法 Pending JP2006525368A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46756703P 2003-05-02 2003-05-02
PCT/US2004/013727 WO2004098524A2 (en) 2003-05-02 2004-05-03 Lipid platinum complexes and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2006525368A JP2006525368A (ja) 2006-11-09
JP2006525368A5 true JP2006525368A5 (ja) 2007-06-14

Family

ID=33435089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006514250A Pending JP2006525368A (ja) 2003-05-02 2004-05-03 脂質白金錯体およびその使用方法

Country Status (6)

Country Link
US (1) US20070160656A1 (ja)
EP (1) EP1622585A4 (ja)
JP (1) JP2006525368A (ja)
AU (1) AU2004235781A1 (ja)
CA (1) CA2524478A1 (ja)
WO (1) WO2004098524A2 (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050425A1 (en) * 2003-05-20 2008-02-28 Jonathan Lewis Combination Chemotherapy Comprising 5-Fluorouracil or a Derivative Thereof and a Liposomal Platinum Complex
EP1631278A4 (en) * 2003-05-20 2006-09-20 Aronex Pharmaceuticals Inc COMBINED CHEMOTHERAPY COMPRISING CAPECITABINE AND A COMPLEX BASED ON LIPOSOMIC PLATINUM
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
EP1737472B1 (en) 2004-03-29 2014-08-13 University Of South Florida Effective treatment of tumors and cancer with triciribine
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
WO2008070136A1 (en) * 2006-12-06 2008-06-12 University Of South Florida Compositions including triciribine and one or more platinum compounds and methods of use thereof
EP2123258A1 (en) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
WO2010140061A2 (en) * 2009-06-03 2010-12-09 John Charles Mayo Formulations for the treatment of deep tissue pain
RS55714B1 (sr) 2010-06-04 2017-07-31 Univ Ohio Fosfaplatini i njihova primena za lečenje kancera
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
CN103665050B (zh) * 2013-08-29 2016-04-27 西北工业大学 一种苯基咪唑邻菲罗啉竹红菌素铂配合物及其制备方法
LT3316856T (lt) 2015-06-30 2021-07-12 Sequessome Technology Holdings Limited Mišrios kompozicijos
CN105481902B (zh) * 2015-12-03 2017-12-05 昆明贵金属研究所 以磷酸二氢根为轴向配体的铂(iv)抗癌化合物
MX2021005110A (es) * 2018-11-02 2021-08-24 Tesorx Pharma Llc Quimioterapia intraperitoneal mejorada con liposomas.
FI4025581T3 (fi) * 2019-09-05 2024-03-01 Vuab Pharma A S Uusia platina(iv)-komplekseja, joilla on olennaisesti suurempi kasvaimen vastainen teho
JP2023519175A (ja) * 2020-03-10 2023-05-10 中原大學 リポソーム組成物及びその調製方法
JP2023523039A (ja) * 2020-04-22 2023-06-01 オンコヴォリューション エル・エル・シー ペプチド白金錯体およびその使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5829957B2 (ja) * 1977-09-12 1983-06-25 喜徳 喜谷 新規な白金錯体
JPS5622724A (en) * 1979-08-02 1981-03-03 Asahi Chem Ind Co Ltd Pharmaceutical preparation of n4-acylcytosine arabinoside
EP0113508A1 (en) * 1982-11-04 1984-07-18 Inco Research & Development Center, Inc. Hydrophobic platinum compounds and their preparation
US5041581A (en) * 1985-10-18 1991-08-20 The University Of Texas System Board Of Regents Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5117022A (en) * 1985-10-18 1992-05-26 The Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5384127A (en) * 1985-10-18 1995-01-24 Board Of Regents, The University Of Texas System Stable liposomal formulations of lipophilic platinum compounds
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5902604A (en) * 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
AU7711096A (en) * 1996-12-03 1998-06-29 Rijsuniversiteit Utrecht Cisplatinum comprising pharmaceutical
US5843475A (en) * 1996-12-06 1998-12-01 Board Of Regents, The University Of Texas System Delivery and activation through liposome incorporation of diaminocyclohexane platinum (II) complexes
PL192633B1 (pl) * 1997-02-05 2006-11-30 Upjohn Co Kompozycja farmaceutyczna i sposób wytwarzania lipidowego kompleksu lub liposomu fosfolipidu i układu diaminocykloheksan-dikarboksylan platyny
EP1319403A4 (en) * 2000-08-11 2009-07-08 Dainippon Sumitomo Pharma Co TREATMENTS AGAINST CANCER TOLERANT IN CISPLATIN
AU2003258075A1 (en) * 2002-08-06 2004-02-23 Lyotropic Therapeutics, Inc. Lipid-drug complexes in reversed liquid and liquid crystalline phases

Similar Documents

Publication Publication Date Title
JP2006525368A5 (ja)
JP2005528325A5 (ja)
JP2017538677A5 (ja)
JP2019512478A5 (ja)
JP2006519852A5 (ja)
JP2017535610A5 (ja)
JP2014510729A5 (ja)
JP2016506916A5 (ja)
JP2009502743A5 (ja)
JP2015512860A5 (ja)
JP2002517491A5 (ja)
JP2006182786A5 (ja)
JP2006523216A5 (ja)
JP2018135343A5 (ja)
JP2019515908A5 (ja)
JP2016503414A5 (ja)
JP2017513908A5 (ja)
JP2008546809A5 (ja)
JP2020530007A5 (ja)
JP2014523413A5 (ja)
JP2013538213A5 (ja)
JP2014516075A (ja) 癌治療のためのメタロセン化合物の使用
JP2020514344A5 (ja)
JP2010539091A5 (ja)
PT701440E (pt) Complexos tri(platinicos)